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A B S T R A C T
Background: Aberrant skeletal muscle mitochondrial oxidative metabolism is a debilitating feature of chronic
diseases such as chronic obstructive pulmonary disease, type 2 diabetes and chronic heart failure. Evidence in
non-muscle cells suggests that glycogen synthase kinase-3β (GSK-3β) represses mitochondrial biogenesis and
inhibits PPAR-γ co-activator 1 (PGC-1), a master regulator of cellular oxidative metabolism. The role of GSK-3β
in the regulation of skeletal muscle oxidative metabolism is unknown.
Aims: We hypothesized that inactivation of GSK-3β stimulates muscle oxidative metabolism by activating PGC-1
signaling and explored if GSK-3β inactivation could protect against physical inactivity-induced alterations in
skeletal muscle oxidative metabolism.
Methods: GSK-3β was modulated genetically and pharmacologically in C2C12 myotubes in vitro and in skeletal
muscle in vivo. Wild-type and muscle-specific GSK-3β knock-out (KO) mice were subjected to hind limb sus-
pension for 14 days. Key constituents of oxidative metabolism and PGC-1 signaling were investigated.
Results: In vitro, knock-down of GSK-3β increased mitochondrial DNA copy number, protein and mRNA abun-
dance of oxidative phosphorylation (OXPHOS) complexes and activity of oxidative metabolic enzymes but also
enhanced protein and mRNA abundance of key PGC-1 signaling constituents. Similarly, pharmacological in-
hibition of GSK-3β increased transcript and protein abundance of key constituents and regulators of mi-
tochondrial energy metabolism. Furthermore, GSK-3β KO animals were protected against unloading-induced
decrements in expression levels of these constituents.
Conclusion: Inactivation of GSK-3β up-regulates skeletal muscle mitochondrial metabolism and increases ex-
pression levels of PGC-1 signaling constituents. In vivo, GSK-3β KO protects against inactivity-induced reductions
in muscle metabolic gene expression.
1. Introduction
Impairments in skeletal muscle oxidative phenotype (OXPHEN),
defined as the collective of cellular features determining fatigue
resistance and capacity for mitochondrial substrate oxidation, are fre-
quently observed in chronic diseases such as chronic obstructive pul-
monary disease (COPD) [1,2], type 2 diabetes mellitus [3] and chronic
heart failure [4], and are also observed during aging [5]. Interestingly,
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these abnormalities, commonly associated with progressive disability
and reduced quality of life in these conditions, are also often associated
with conditions of muscle mass loss such as cachexia and sarcopenia
[6–8]. Although the exact molecular mechanisms and triggers under-
lying muscle abnormalities in these conditions remain incompletely
understood, physical inactivity and disuse of skeletal musculature likely
constitute an important contributing factor [9,10].
Besides the well-known exercise-induced potentiation of mi-
tochondrial metabolism and muscle contractile function [11,12], a
wealth of evidence demonstrates that anabolic stimuli like insulin or
insulin-like growth factor-I (IGF-I) can induce muscle hypertrophy [13].
It is clear that the IGF/phosphoinositide-3-kinase (PI3K)/protein kinase
B (Akt) pathway regulates muscle mass by controlling protein turnover
by modulation of protein synthesis and protein breakdown [13–15].
However, whether or not Akt signaling is involved in the control of
muscle mitochondrial metabolism is largely unexplored. Glycogen
synthase kinase-3β (GSK-3β) is a direct target of Akt which phosphor-
ylates GSK-3β on Ser9 reducing its kinase activity. Previous, our group
reported that GSK-3β inactivation is essential for muscle mass regula-
tion as GSK-3β has a pivotal role in the determination of muscle mass
by controlling muscle protein- and myonuclear turnover [15–17].
Intriguingly, in recent years, evidence emerged indicating a role for
GSK-3β in the regulation of mitochondrial metabolism in non-muscle
cells. More specifically, GSK-3β inhibition using lithium chloride (LiCl)
potently induced mitochondrial biogenesis in endothelial and neuronal
cells [18,19], which was accompanied by an increase in activity of the
peroxisome proliferator-activated receptor (PPAR)-γ co-activator 1
(PGC-1) signaling network, a key signaling pathway controlling cellular
oxidative metabolism. In line with these results, PGC-1α protein levels
increased in vascular smooth muscle after treatment with LiCl [20].
Whether or not GSK-3β plays a role in the regulation of mitochondrial
metabolism in muscle thus far is unexplored.
PGC-1α, and to a lesser extent its family member PGC-1β, is a key
player in the regulation of fatty acid (FA) β-oxidation (FAO), oxidative
phosphorylation (OXPHOS), mitochondrial biogenesis as well as mi-
tochondrial DNA (mtDNA) replication [21]. PGC-1 acts on these pro-
cesses by co-activating several nuclear proteins with transcriptional
activity such as estrogen-related receptors (ERRs), PGC-1 and ERR-in-
duced regulator in muscle 1 (PERM1) [22], PPARs [23] and nuclear
respiratory factor 1/2α (NRF-1/2α) [24]. Also, PGC-1 co-activates
transcription of the promoter of the gene encoding mitochondrial
transcription factor A (TFAM) [24], a key protein involved in tran-
scription of the mitochondrial genome and mitochondrial biogenesis.
Impairments in this regulatory molecular network have been shown in
muscle biopsies of diabetic [25] and COPD [26] patients. In addition,
studies using different experimental modalities of inactivity or limb
immobilization have demonstrated that physical inactivity-induced loss
of muscle mitochondrial capacity is associated with decreased abun-
dance/activity of key constituents of the PGC-1 signaling pathway in
both mouse and human [27,28].
In the present study, we genetically and pharmacologically modulated
GSK-3β in C2C12 myotubes and investigated the impact on mitochondrial
metabolism and its regulation by the PGC-1 signaling network.
Furthermore, as a proof of concept, we subsequently explored the in vivo
physiological relevance of a potential role of GSK-3β in the regulation of
muscle mitochondrial metabolism by subjecting wild-type (WT) and
skeletal muscle-specific GSK-3β knock-out (KO) mice to a 14-day hind
limb suspension (HLS) protocol known to detrimentally impact muscle
mitochondrial capacity and its regulation by PGC-1 [28,29].
2. Materials and methods
2.1. Cell culture
C2C12 murine myoblasts were cultured as previously described [15].
Briefly, myoblasts were cultured in low-glucose (1 g/l) Dulbecco's modified
Eagle's medium (DMEM) (GIBCO, Carlsbad, CA, USA) growth medium
(GM) enriched with 9% (vol/vol) fetal bovine serum (FBS) (PAA Labora-
tories, Pasching, Austria) and antibiotics (50 U/ml penicillin and 50 μg/ml
streptomycin; both from GIBCO). The cells were plated in BD Matrigel-
coated 6-well plates at a density of 1 ∗ 104 cells/cm2. Cells were cultured
for 24 h in GM before initiation of differentiation, by growth factor with-
drawal [30] using differentiation medium (DM), which consisted of low-
glucose DMEM+GlutaMAX™ (GIBCO) with pyruvate, supplemented with
0.5% heat-inactivated FBS (30 min at 56 °C) and antibiotics (50 U/ml pe-
nicillin and 50 μg/ml streptomycin). The differentiating cells were pro-
vided with fresh DM on day 1, 3 and 5 of differentiation.
2.2. Treatment
GSK-3β (MSS226316, Thermo Scientific, Boston, MA, USA) or GSK-
3α (MSS286308, Invitrogen, Carlsbad, CA, USA) mRNA expression was
silenced in C2C12 myotubes that had undergone differentiation for
5 days and were grown in 6-well plates. The myotubes were transiently
transfected using stealth RNAi small interfering (si)RNAs (Invitrogen)
according to the manufacturer's guidelines. The transfection mix was
prepared in Opti-MEM reduced serum medium (Invitrogen), and
Lipofectamine RNAiMAX (Invitrogen) was used as transfection agent.
The transfection mixture, for both universal control siRNA (low GC
scrambled control; Invitrogen) and target siRNA (final concentration
both at 10 nM), was incubated at room temperature (RT) for 20 min,
and added to the culture plates containing fresh DM. CHIR99021
(CHIR) (#361559, Calbiochem, San Diego, CA, USA), a specific GSK-
3α/β inhibitor, was used to pharmacologically inhibit GSK-3α/β with a
final concentration of 7 μM. Adenoviral over-expression was used to
over-express GSK-3β or green fluorescent protein (GFP) as a control in
C2C12 myotubes that had undergone differentiation for 5 days and
were grown in 6-well plates after new DM was supplied.
2.3. Cell processing
C2C12 myotubes were washed twice with pre-cooled 1X Hank's
balanced salt solution (HBSS) and harvested in RLT buffer (Qiagen,
Hilden, Germany) containing β-mercaptoethanol (1:100) for RNA iso-
lation, whole cell lysates buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1%
Nonidet P40) with PhosSTOP and complete protease inhibitors (both
Sigma-Aldrich, St. Louis, MO, USA) for Western Blotting, DNA lysis
buffer (0.1 M Tris/HCl pH 8.5, 5 mM EDTA pH 8.0, 0.2% SDS and 0.2 M
NaCl) for DNA isolation or 0.5% Triton X in HBSS for enzyme activity
assays using cell scrapers (rubber policemen). For enzymatic activity
assays, samples were spun down for 2 min at maximal speed at 4 °C and
dissolved in 1% BSA in lysis buffer before storing at −80 °C.
2.4. Animals
The animal study described here was approved by the Institutional
Animal Care Committee of Maastricht University (DEC-2009-074).
Male skeletal muscle-specific GSK-3β KO animals on a C57/Bl6 back-
ground were generated by breeding GSK-3βfl/fl MLC1f-Cre+/−
(muscle-specific GSK-3β KO) with GSK-3βfl/fl MLC1f-Cre−/− (Wild-
type Ctrl/WT) mice [31]. Double Cre-negative litter mates served as
‘WT’ controls. At the start of the experiment mice were 13 weeks old
(young adults). Animals were housed in a temperature-controlled room
(21–22 °C) with 12:12 h light–dark cycle, and had ad libitum access to
standard chow pellets and water. Animals were randomly divided into 2
groups for each genotype, and were subsequently subjected to no ex-
perimental procedures (baseline (BL)) or 14 days of HLS. The group size
for the BL-groups was n = 9 and for the HLS-groups n = 8 [32]. In
brief, a tail harness was placed while mice were lightly anesthetized
using isoflurane inhalation. HLS was accomplished using a tail sus-
pension device consisting of a plastic-coated iron wire taped around the
mouse's tail and connected to a swivel hook to allow circular motility.
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The latter was attached to a Teflon-coated PVC ring, which slid over an
iron rod spanning the length of the cage to allow longitudinal motility.
The mice were raised so as to prevent the hind limbs from touching the
cage floor or sides. In this way, four HLS mice could be housed in one
standard cage. During the whole experiment body weight and water
consumption were monitored. After euthanasia with sodium pento-
barbital at BL or after HLS, M. gastrocnemius muscle was dissected using
standardized dissection methods, cleaned of excess fat and tendon/
connective tissue, pair weighed on an analytical balance, snap frozen in
liquid nitrogen, and stored at −80 °C for further processing.
2.5. Quantitative real-time PCR
cDNA was synthesized from 400 ng mRNA using the tetro cDNA
synthesis kit (Bioline, Singapore, Singapore) according to manufac-
turer's guidelines. cDNA was diluted (1:50) in nuclease-free H2O and
stored at 4 °C, cDNA stocks were stored at −20 °C. Each qRT-PCR re-
action contained 4.4 μl diluted cDNA, 5 μl SyBr-green qPCR mastermix
(Bioline) and 0.6 μl primers containing 5 μM of both the forward and
the reverse primer per sample. The samples were run in a white 384-
well plate (Roche, Basel, Switzerland), which was sealed and spun
down. qRT-PCR was performed on a Roche LightCycler480 system for
10 min at 95 °C followed by 45 cycles of 15 s at 95 °C and 30 s at 60 °C.
Melt curves were made using a gradual increase in temperature of
0.11 °C/s with 5 acquisitions/s and a temperature range of 60 °C to
90 °C. The melt curves were checked for double peaks and the negative
controls were checked using the LightCycler480 software (Roche). Gene
expression of genes of interest was analyzed using LinRegPCR software.
The expression of these genes of interest was normalized with a cor-
rection factor calculated by GeNorm [33] based on the expression levels
of Rpl13a, Hprt, CycloA and β2M as reference genes. The sequences of
the used primers are listed in Table 1.
2.6. DNA isolation
Proteinase K was added (final concentration is 0.2 mg/ml) to the
lysates and incubated overnight at 55 °C. Lysates were spun down for
5 min at full speed and DNA from the supernatants was precipitated
with isopropanol. DNA pellets were washed twice with 70% ethanol.
When all ethanol was evaporated DNA pellets were dissolved in 250 μl
10 mM Tris/HCl pH 8.0 and heated to 55 °C for 2 h followed by over-
night incubation at 4 °C. When dissolved, the DNA was diluted 100× in
TE buffer and CoxII and CycloA levels were determined as described in
Section 2.5.
2.7. Western blot analysis
Samples were thawed, spun down for 2 min at maximal speed at
4 °C and total protein content was assessed in the supernatant with the
Thermo Scientific Pierce BCA protein assay kit (Pierce) according to
manufacturer's guidelines. The supernatants were diluted in Laemmli
sample buffer to 1× as final concentration (0.25 M Tris·HCl pH 6.8; 8%
(wt/vol) SDS; 40% (vol/vol) glycerol; 0.4 M DTT and 0.04% (wt/vol)
bromophenol blue), adjusted to 0.5–1 μg/μl and boiled for 5 min at
95 °C. The samples of both the in vitro as the in vivo work were loaded,
between 5 and 15 μg protein per lane (depending on the antibody), on a
Criterion XT Precast 4–12% Bis-Tris gel (BioRad, Hercules, CA, USA).
Proteins were separated by electrophoresis with 100-140 V. The pro-
teins on the gel were transferred to a 0.45-μm Whatman Protran
Nitrocellulose Transfer membrane (Whatman) by electroblotting
(BioRad Criterion Blotter) with 100 V for 1 h. Ponceau S staining (0.2%
Ponceau S in 1% acetic acid; Sigma-Aldrich) was performed and cap-
tured using the Amersham 600 imager (GE Healthcare, Chalfont St.
Giles, UK), to quantify total protein loading. Blots were blocked for 1 h
using 3% non-fat dry milk (FrieslandCampina, Amersfoort, the
Table 1
qPCR primer sequences.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
Gsk-3β CCACATGCTCGGATTCAGGC TGTCCACGGTCTCCAGCATTAGTAT
Gsk-3α CCCTCACCACTTCCTACAACCCA TTGTGGCATCAGATGGCTGC
Ndufb3 ACAGACAGTGGAAAATTGAAGGG GCCCATGTATCTCCAAGCCT
Sdhb AATTTGCCATTTACCGATGGGA AGCATCCAACACCATAGGTCC
Cyc1 GCATTCGGAGGGGTTTCCAG CCGCATGAACATCTCCCCA
HkII AACCTCAAAGTGACGGTGGGC AAGGACACGTCACATTTCGGAGC
Pfkfb3 AGAACTTCCACTCTCCCACCCAAA AGGGTAGTGCCCATTGTTGAAGGA
Glut1 TGACCATCGCCCTGGCCT GGACCAGGGCCTACTTCAAAGAAG
Glut4 GATGCCGTCGGGTTTCCAGCA TGAGGGTGCCTTGTGGGATGG
Cox II CCATCCCAGGCCGACTAA ATTTCAGAGCATTGGCCATAGAA
Pdk-4 AGGTTATGGGACAGACGCTATCATCTACT AGACTGGGAGCTTTTCTACAGACTCAGA
Acadvl AGACGGAGGACAGGAATCGG ACCACGGTGGCAAATTGATC
Pgc-1α CAACAATGAGCCTGCGAACA CTTCATCCACGGGGAGACTG
Pgc-1β ACCCTGAGAAAGCGCAATGA CCCAGATGAGGGAAGGGACT
Errα GGCGGACGGCAGAAGTACAAA GCGACACCAGAGCGTTCAC
Perm1 GCTTAACAGTCAGGAAGGCAGGG ACAGCCCAAGTGGCAAAGGCAAC
Pparα ACTACGGAGTTCACGCATGTG TTGTCGTACACCAGCTTCAGC
Pparδ AGGCCCGGAGCATCCTCA TGGATGACAAAGGGTGCGTTG
Nrf-1 AGCCACATTGGCTGATGCTT GGTCATTTCACCGCCCTGTA
Nrf-2α TGCTGCACTGGAAGGCTACA TTACCCAAACCACCCAATGC
Tfam CCGGCAGAGACGGTTAAAAA TCATCCTTTGCCTCCTGGAA
Sirt1 ACAGTGAGAAAATGCTGGCCTAA CCTCAGCACCGTGGAATATGT
Reference genes
β2M CTTTCTGGTGCTTGTCTCACTGA GTATGTTCGGCTTCCCATTCTC
Rpl13a CACTCTGGAGGAGAAACGGAAGG GCAGGCATGAGGCAAACAGTC
CycloA TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG
Hprt TGGATATGCCCTTGACTATAATGAGTAC AGGACTCCTCGTATTTGCAGATTC
Gsk-3α/β: glycogen synthase kinase-3α/β, Ndufb3: NADH:Ubiquinone Oxidoreductase Subunit B3, Sdhb: Succinate Dehydrogenase Complex Iron Sulfur
Subunit B, Cyc1: cytochrome C1, COX: Cytochrome c oxidase, Acadvl: very long-chain specific acyl-CoA dehydrogenase, HkII: hexokinase II, Pfkfb3: 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, Glut: glucose transporter, Pparα/δ: peroxisome proliferator-activated receptor α/δ, Pgc-1α/β: PPAR
gamma coactivator-1α/β, Errα: estrogen-related receptor α, Nrf-1/2α: nuclear respiratory factor-1/2α, Tfam: mitochondrial transcription factor A, Sirt1:
sirtuin 1, Perm1: PGC-1 and ERR-induced regulator in muscle 1, β-2M: β-2 microglobulin, Rpl13a: ribosomal protein L13a, CycloA: cyclophilin A and Hprt:
hypoxanthine-guanine phosphoribosyltransferase.
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Netherlands) and incubated overnight at 4 °C with primary antibodies
directed to: GSK-3β (610201, BD Biosciences, San Jose, CA, USA), GSK-
3α and PGC-1α (24259 and 516557, Merck Millipore, Billerica, MA,
USA), total OXPHOS (Mitosciences, Eugene, OR, USA), phosphorylated
eukaryotic translation initiation factor 2β (p-eIF2Bε), phosphorylated
glycogen synthase (p-GS) and hexokinase II (HKII) (all from Cell
Signaling Technology, Beverly, MA, USA) diluted in Tris-buffered saline
with 0.1% Tween 20. The blots were probed with a peroxidase-con-
jugated secondary antibody (no. PI-1000) (Vector Laboratories,
Burlingame, CA, USA) and visualized using SuperSignal West Pico or
SuperSignal West Femto Chemiluminescent Substrate (both Pierce
Biotechnology) according to the manufacturer's instructions. The
Western blots were digitalized using the Amersham 600 imager, and
subsequent quantification was done using ImageQuant TL software (GE
Healthcare).
2.8. Enzyme activity assays
Total protein content was assessed by Thermo Scientific Pierce BCA
protein assay kit (Pierce Biotechnology) and used as a correction factor.
Enzymatic activities of citrate synthase (CS; EC 2.3.3.1) [34] and β-
hydroxyacyl-CoA dehydrogenase (HAD; EC 1.1.1.35) [35] were ana-
lyzed spectrophotometrically at 412 nm and 340 nm, respectively as
previously described using a Multiskan Spectrum plate reader (Thermo
Labsystems, Breda, The Netherlands) at 37 °C with a 30 s interval for a
total duration of 30 min.
2.9. Statistical analysis
Data were analyzed using an unpaired student's t-test or one-way
ANOVA with a Bonferroni as post-hoc test with GraphPad Prism 5.0
software (GraphPad, Prism, La Jolla, CA, USA). Significant differences
are indicated as p < 0.05 in each figure. Data are expressed as
mean ± SEM. Graphs were made using GraphPad Prism 5.0 software
and representative blots were added using Adobe illustrator CS6 soft-
ware (Adobe Systems Incorporated, San Jose, CA, USA).
3. Results
3.1. GSK-3β knock-down increases mitochondrial content
Knock-down of GSK-3β, verified by a 80–90% decrease in GSK-3β
mRNA and protein abundance as well as reduced phosphorylation
status of a direct downstream target of GSK-3β (eIF2Bε) (Fig. S1),
significantly enhanced myotube mitochondrial oxidative metabolism.
This was evidenced by an increased mitochondrial DNA copy number
(Fig. 1A) and elevated CS enzyme activity (Fig. 1B). Moreover, en-
zymatic activity and protein- and mRNA transcript abundance of key
constituents of the electron transport chain (nuclear- and mitochon-
drial-encoded OXPHOS sub-units) and mitochondrial fatty acid β-
oxidation pathway (HAD and Acadvl: very long-chain specific acyl-
CoA dehydrogenase) were significantly up-regulated after knock-
down of GSK-3β (Fig. 1C, D). This apparent enhancement of cellular
oxidative metabolism after knock-down of GSK-3β protein was also
associated with increased elevated HKII protein levels and increased
mRNA transcript abundance of the glycolytic genes HkII, 6-phos-
phofructo-2-kinase/fructose-2,6-biphosphatase 3 (Pfkfb3), glucose
transporter-1 (Glut-1) and Glut-4. Pyruvate dehydrogenase kinase-4
(Pdk-4) mRNA expression also increased after GSK-3β knock-down
(Fig. S2).
3.2. GSK-3β knock-down increases expression levels of key components of
the PGC-1 signaling network
Enhancement of mitochondrial content after knock-down of GSK-3β
was associated with increased PGC-1α protein abundance and a potent
8–10-fold increase in Pgc-1α mRNA transcript levels (Fig. 2A, B). Ad-
ditionally, knock-down of GSK-3β also resulted in a marked increase in
transcript levels of several PGC-1-co-activated transcription factors
heavily involved in fatty acid oxidation, fatty acid transport and mi-
tochondrial substrate metabolism including Pparα, Pgc-1β, Errα and the
recently identified PGC-1-ERRα-co-activated transcription factor Perm1
(Fig. 2D).
3.3. Pharmacological GSK-3 inhibition enhances myotube oxidative gene
expression
Interestingly, we observed that knock-down of the GSK-3β protein
resulted in increased mRNA- and protein abundance of the GSK-3α
isoform, which coincided with an increased phosphorylation status of
the well-known GSK-3 phosphorylation target glycogen synthase (GS)
(Fig. S3). To explore a potential role for GSK-3α in the regulation of
muscle mitochondrial metabolism, but also to investigate whether or
not pharmacological inhibition of GSK-3 activity exerts similar effects
on myotube oxidative gene expression compared to specific physical
absence of the GSK-3β protein (as shown in Figs. 1 and 2), we designed
experiments in which the presence and/or activity of the 2 GSK-3 iso-
forms was modulated.
Firstly, pharmacological inhibition of both GSK-3 isoforms by
CHIR, as shown by a potent decrease in phosphorylated eIF2Bε (Fig.
S4), significantly increased transcript levels of genes involved in
OXPHOS (CII and III sub-units) and fatty acid oxidation (Acadvl)
(Fig. 3A, B). In addition, CHIR also up-regulated expression levels of
key constituents of the PGC-1 signaling network (Pgc-1α, Errα and
Perm1) (Fig. 3C). Similar to the findings obtained following knock-
down of GSK-3β, pharmacological inhibition of GSK-3 with CHIR also
resulted in increased mRNA expression of several genes involved in
glycolysis (HkII, Pfkfb3 and Glut-1) (Fig. S5). Pharmacological in-
activation of GSK-3 with CHIR, however, did not further enhance
siGSK-3β-induced increases in mRNA levels of constituents and reg-
ulators of myotube oxidative metabolism (data not shown). As de-
picted in Fig. S6, specific knock-down of the GSK-3α protein resulted
in increased transcript levels of Pgc-1α although this was less pro-
nounced compared to GSK-3β knock-down. Furthermore, knock-
down of GSK-3α did not affect transcript levels of genes involved in
OXPHOS (CI, CII and CIII sub-units), glycolysis (HkII and Glut-1),
PGC-1 or PGC-1 co-activated transcription factors (Pgc-1β, Pparα, Errα
and Perm1) showing that although pharmacological inhibition of
GSK-3α/β recapitulates the effects of knock-down of GSK-3β on me-
tabolic gene expression, GSK-3β appears to be the predominant GSK-3
isoform involved in suppression of mitochondrial energy metabolism.
3.4. PGC-1α is required for increased OXPHOS gene expression induced by
GSK-3 inhibition
In order to explore whether increases in metabolic gene expression,
induced by GSK-3 inhibition, are PGC-1α-dependent, we knocked-down
Pgc-1α in C2C12 myotubes and subsequently inhibited GSK-3 using
CHIR. Knock-down of Pgc-1α (Fig. 4A) prevented CHIR-induced in-
creases in Pgc-1α mRNA as well as inductions of known PGC-1α-de-
pendent target genes including genes encoding for OXPHOS sub-units
(CII and CIII) [36] (Fig. 4B) as well as Errα [37,38] (Fig. 4C).
3.5. Over-expression of GSK-3β in myotubes does not affect oxidative gene
expression
Next, in order to explore whether over-expression of GSK-3β has
opposite effects on myotube metabolic gene expression compared to
knock-down of the protein, we used an adenoviral system to over-ex-
press GSK-3β. Over-expression of GSK-3β resulted in an approximate
3.5 fold increase in Gsk-3β mRNA and protein abundance as well as
increased phosphorylation levels of its down-stream target eIF2Bε (Fig.
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S7). However, GSK-3β over-expression did not alter the expression of
any of the metabolic genes or genes involved in the PGC-1α signaling
pathway (Fig. S8A-D) that were investigated. Moreover, over-expres-
sion of GSK-3β did not change protein content of OXPHOS subunits
(Complex, I, II, III and V) compared to myotubes over-expressing GFP as
control (Fig. S8A).
3.6. GSK-3β knock-out protects against disuse-induced loss of oxidative
gene expression in skeletal muscle
Having established that the physical absence or pharmacological
inhibition of the GSK-3β protein in cultured myotubes enhanced cel-
lular mitochondrial metabolism and up-regulated PGC-1 signaling, we
Fig. 1. GSK-3β knock-down increases mitochondrial con-
tent. C2C12 myotubes were differentiated for 5 days and
transfected with siRNA constructs targeting GSK-3β (grey)
or a low GC scrambled control (white). Myotubes were
harvested at different time-points post-transfection (48 h
for mitochondrial DNA copy number, transcript- and pro-
tein levels or 72 h for enzymatic activities). (A)
Mitochondrial DNA copy number, (B) CS activity, (C) pro-
tein levels of different complexes of the respiratory chain
and gene expression of nuclear-encoded sub-units (Ndufb3,
Sdhb and Cyc1 respectively Complex I, II and III) and the
mitochondrial-encoded sub-unit (CoxII, respectively
Complex IV) and (D) HAD enzyme activity and mRNA le-
vels of Acadvl all are given in fold changes compared to
control. Representative pictures of the blots are shown and
Western blot data is corrected for total protein loading as-
sessed by Ponceau S staining. Black boxes around the re-
presentative pictures indicate that they are cut from the
same Western blot. All data are expressed as means ± SEM
from n = 4/experimental condition (mRNA) or n = 6/ex-
perimental condition (mitochondrial DNA copy number,
protein and enzyme) (n = 3 experiments), *p≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001 vs. siControl. GSK-3β: glycogen
synthase kinase-3β, mtDNA: mitochondrial DNA, CS: citrate
synthase OXPHOS: oxidative phosphorylation, Ndufb3:
NADH:Ubiquinone Oxidoreductase Subunit B3, Sdhb: suc-
cinate dehydrogenase complex iron sulfur subunit B, Cyc1:
cytochrome c 1, CoxII: Cytochrome c oxidase II, HAD: β-
hydroxyacyl-CoA dehydrogenase and Acadvl: very long-
chain specific acyl-CoA dehydrogenase.
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subsequently explored the physiological relevance of muscle-specific
ablation of GSK-3β in vivo with regard to mitochondrial metabolism and
its regulation of the PGC-1 signaling network. To address this, we
submitted WT and skeletal muscle-specific GSK-3β KO animals to a 14-
day HLS protocol.
Previously, for both genotypes 10% body weight loss was reported
after the 14-day HLS protocol, although body weight loss was sig-
nificantly less in the GSK-3β KO animals on day 2 of HLS. Furthermore,
BL M. gastrocnemius muscle mass was similar between WT and GSK-3β
KO animals and HLS comparably decreased muscle mass in both WT
(16.9% ± 2.7%) and GSK-3β KO (16.3% ± 2.2%) animals [39].
Fourteen days of HLS reduced protein and mRNA levels of OXPHOS
complex sub-units in WT animals (Fig. 5A, B), while this was not ob-
served in GSK-3β KO animals. Glycolytic protein and gene expression
were largely unaltered by the unloading protocol in both genotypes
(Fig. S9A, B). In addition, Pdk-4mRNA expression was potently reduced
after 14 days of HLS in GSK-3β KO animals (Fig. S9B) while gene ex-
pression of Acadvl was found to decrease in M. gastrocnemius after HLS
in both genotypes (Fig. 5C).
3.7. GSK-3β ablation protects against unloading-induced changes in the
PGC-1 signaling network
Besides the protective effect of GSK-3β KO on unloading-induced
decrements in protein and mRNA levels of OXPHOS subunits, muscle-
specific GSK-3β KO animals were also protected against unloading-in-
duced decrements in expression levels of key regulators of mitochon-
drial biogenesis. This was evidenced by a significant reduction of NRF-1
protein in WT animals after unloading, which was not detected in GSK-
3β KO animals, PGC-1α and TFAM protein levels did not change sig-
nificantly in both genotypes after 14 days of HLS (Fig. 6A). However,
transcript levels of Pgc-1β, Tfam, Pparα and Errα were significantly re-
duced in WT animals after 14 days of HLS, whereas these unloading-
induced decreases were not present in muscle-specific GSK-3β KO an-
imals (Fig. 6B). In addition, other constituents involved in the PGC-1
signaling network, namely Nrf-1, Nrf-2α, sirtuin 1 (Sirt1) and Pparδ were
unaltered after HLS in WT animals, while expression levels of these
genes were significantly induced in muscle-specific GSK-3β KO animals.
Furthermore, Perm1 gene expression tended to decrease in GSK-3β KO
animals after HLS (Fig. 6B).
Fig. 2. GSK-3β knock-down increases transcript levels of
key components of the PGC-1 signaling network. C2C12
myotubes were differentiated for 5 days and transfected
with siRNA constructs targeting GSK-3β (grey) or a low GC
scrambled control (white). Myotubes were harvested 48 h
post-transfection. (A) Protein content of PGC-1α, (B) mRNA
expression of Pgc-1α and (C) mRNA expression of Pgc-1β
and transcription factors involved in PGC-1α signaling. A
representative picture of a blot is shown and Western blot
data is corrected for total protein loading assessed by
Ponceau S staining. All data are expressed as
means ± SEM from n = 4/experimental condition
(mRNA) or n = 6/experimental condition (protein) (n = 3
experiments), *p≤ 0.05, ***p ≤ 0.001 vs. siControl. GSK-
3β: glycogen synthase kinase-3β, Pparα/δ: peroxisome
proliferator-activated receptor α/δ, Pgc-1α/β: PPAR gamma
coactivator-1α/β, Errα: estrogen-related receptor α, Nrf-1/
2α: nuclear respiratory factor-1/2α, Tfam: mitochondrial
transcription factor A, Sirt1: sirtuin 1 and Perm1: PGC-1 and
ERR-induced regulator in muscle 1.
Fig. 3. Pharmacological inactivation of GSK-3 increases oxidative metabolic gene ex-
pression in myotubes. C2C12 myotubes were differentiated for 5 days and treated with
CHIR99021 (grey) (final concentration: 7 μM) or DMSO as vehicle (white) and transfected
with a low GC scrambled control siRNA. Myotubes were harvested 48 h post-treatment.
Gene expression of (A) OXPHOS sub-units CII (Sdhb) and CIII (Cyc1), (B) Acadvl and (C)
Pgc-1α and transcription factors involved in PGC-1α signaling. All data are expressed as
means ± SEM from n = 3/experimental condition (n = 3 experiments), *p≤ 0.05,
**p ≤ 0.01, #p ≤ 0.1 vs. VC. OXPHOS: oxidative phosphorylation, Sdhb: succinate de-
hydrogenase complex iron sulfur subunit B, Cyc1: cytochrome c 1, Acadvl: very long-chain
specific acyl-CoA dehydrogenase, Pparα: peroxisome proliferator-activated receptor α,
Pgc-1α: PPAR gamma coactivator-1α, Errα: estrogen-related receptor α and Perm1: PGC-1
and ERR-induced regulator in muscle 1.
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4. Discussion
In skeletal muscle, GSK-3β has been appreciated for its regulatory
role in glycogen metabolism and protein turnover (for review see [40]).
However, the role of GSK-3β in muscle mitochondrial oxidative meta-
bolism has not been studied thus far. In this study, we show for the first
time that knock-down as well as pharmacological inhibition of the GSK-
3β protein kinase stimulates oxidative phenotype and its regulation by
the PGC-1 signaling network in cultured C2C12 myotubes which was
evidenced by increases in abundance and activity levels of key con-
stituents of mitochondrial substrate metabolism and increased expres-
sion levels of PGC-1 signaling constituents. Furthermore, we showed
that knock-down of Pgc-1α prevented increases in mRNA expression of
OXPHOS sub-units induced by pharmacological GSK-3 inhibition. In
contrast, over-expression of GSK-3β failed to result in any alterations in
metabolic gene expression and PGC-1-co-activated events, suggesting
that in homeostatic conditions endogenous GSK-3β levels are sufficient
to exert maximal control over the regulation of oxidative energy me-
tabolism. In addition to our in vitro data showing that knock-down of
GSK-3β enhances mitochondrial metabolism and the PGC-1 signaling
network in cultured C2C12 myotubes, muscle-specific GSK-3β KO in
vivo protected against unloading-induced decrements in expression le-
vels of key constituents of muscle mitochondrial metabolism and the
PGC-1 signaling network.
In our study we show that genetic or pharmacological inactivation
of GSK-3β, a direct downstream phosphorylation target of Akt, stimu-
lates muscle cell oxidative phenotype. The PI3K/Akt/GSK-3 signaling
axis is highly conserved amongst species and well-known for its reg-
ulatory role in muscle protein synthesis, growth and survival [41]. In-
terestingly, although the exact molecular mechanisms remain elusive to
date, recent reports suggest involvement of the PI3K/Akt/GSK-3 sig-
naling axis in the regulation of cellular energy metabolism. For ex-
ample, in skeletal muscle, Akt-dependent secretion of the myokine
Musclin increases mitochondrial biogenesis in response to physical
activity [42]. In addition, recently, one study in skeletal muscle showed
that IGF-I/Akt-mediated phosphorylation and subsequent activation of
ATP citrate lyase improved mitochondrial function in skeletal muscle
[43]. These studies suggest that activation of Akt, potentially partly via
inactivation of GSK-3β, can improve oxidative metabolism in skeletal
muscle. This notion is in line with our data as we show for the first time
potent inductions in OXPHOS protein and mRNA abundance upon in-
activation GSK-3β in myotubes. Interestingly, evidence in non-muscle
cells support our findings as these studies indicate that inhibition of
GSK-3β similarly resulted in enhanced mitochondrial biogenesis. For
example, in adipocytes OXPHOS protein abundance was shown to in-
crease upon inhibition of GSK-3β with LiCl [44]. Furthermore, LiCl
treatment increased expression levels of mitochondrial- and nuclear-
encoded subunits of OXPHOS complexes in cortical neuronal [19] and
aortic endothelial cells [18].
In addition to increases in transcript and protein abundance and
activity of key proteins involved mitochondrial oxidative substrate
metabolism, we also observed increased protein levels of HKII and
increased transcript abundance of genes heavily involved in glyco-
lysis following either knock-down or pharmacological inhibition of
Fig. 4. Pharmacological inactivation of GSK-3 increases
oxidative gene expression in a Pgc-1α-dependent
manner. C2C12 myotubes were differentiated for 5 days
and treated with siRNA constructs targeting PGC-1α or a
low GC scrambled control and treated with CHIR99021
(final concentration: 7 μM) or DMSO as vehicle on day 6
of differentiation. Myotubes were harvested 48 h post
CHIR treatment. Gene expression of (A) Pgc-1α, (B)
OXPHOS sub-units CII (Sdhb) and CIII (Cyc1) and (C)
Errα is expressed as means ± SEM from n = 3/experi-
mental condition (n = 3 experiments), *p≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001. OXPHOS C: oxidative phos-
phorylation complex, Pgc-1α: PPAR gamma coactivator-
1α, Sdhb: succinate dehydrogenase complex iron sulfur
subunit B, Cyc1: cytochrome c 1 and Errα: estrogen-re-
lated receptor α.
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GSK-3. This is in line with available literature that showed that Akt
activation increased glycolysis in cancer cells and immortalized
mouse kidney epithelial cells [45,46]. Moreover, increased Akt ac-
tivity resulted in higher mitochondrial-bound HKII by direct phos-
phorylation and inhibition of GSK-3β. The mitochondrial-bound HKII
forms a link between glycolysis and oxidative phosphorylation
through better accessibility to generated ATP [47]. However, we also
report a higher Pdk-4 gene expression upon both knock-down or
pharmacological inhibition of GSK-3, suggesting an increased block
on pyruvate input in the TCA cycle originating from glycolysis. PGC-
1α is known to regulate Pdk-4 gene expression via co-activation of
ERRα [48], which could explain the increase in Pdk-4 mRNA ob-
served in our study. Increased Pdk-4 is indicative of inhibition of
oxidative processing of glucose and a switch to FA use as a substrate
for mitochondrial ATP production [49]. We did not measure FAO
following GSK-3β knock-down in the current study. However, we did
show increased activity of HAD, an important enzyme involved in
FAO, after knock-down of GSK-3β in myotubes. Measuring HAD ac-
tivity has been reported to be reflective of FAO activity [50]. As such,
these data highlight the potential role of GSK-3β inactivation in ac-
tive fuel selection in skeletal muscle. However, why inactivation of
GSK-3β was not only associated with increased Pdk-4 mRNA levels
and increased expression or activity of key constituents of fatty acid
β-oxidation but also with increased expression of glycolytic genes
remains unclear. Although PDK-4 is mainly controlled at the tran-
scriptional level, we did not directly measure PDK-4 protein
abundance or activity or glycolytic input in the TCA cycle precluding
conclusions regarding this.
Mitochondrial biogenesis is heavily controlled by PGC-1 and the
downstream co-activation of several nuclear receptors [21,51]. In our
study we showed a 10-fold increase in Pgc-1α gene expression and a
significant increase in PGC-1α protein levels after knock-down of GSK-
3β. Additionally, we report increased expression levels of several other
key components of the PGC-1 signaling network, like ERRα and
PERM1, in C2C12 myotubes after either knock-down of the GSK-3β
protein or pharmacological inhibition of GSK-3 with CHIR. This is in
line with the effect of LiCl on Pgc-1α mRNA expression in various other
cell types. For example, LiCl treatment in aortic endothelial cells re-
sulted in increased Pgc-1α transcript levels [18]. Furthermore, in vas-
cular smooth muscle, GSK-3β inhibition resulted in increased PGC-1
signaling [20]. In addition, during megakaryocyte development, GSK-
3β inhibition using LiCl not only increases mitochondrial density and
mtDNA copy number, but also increases important constituents of the
PGC-1 signaling cascade [52]. In line with these findings, other studies
reported that activation of Akt (thereby inhibiting GSK-3) resulted in
similar findings [53]. For example, Ling et al. showed increased Pgc-1α
transcription following insulin treatment, known to activate Akt [54].
Moreover, the ginsenoside Rg3 significantly increased insulin-stimu-
lated Akt phosphorylation and Pgc-1α gene expression in C2C12 myo-
tubes [55]. However, Kim et al. [55] did not report the phosphorylation
status of GSK-3. In contrast, one study showed a 3-fold decrease in Pgc-
1α mRNA expression upon expression of constitutively active Akt in
Fig. 5. GSK-3β knock-out partially protects
against unloading-induced decline in oxidative
gene expression. Muscle-specific GSK-3β KO
mice and WT littermates were subjected to HLS
for 14 days. M. gastrocnemius was prepared for
western blotting and qPCR analysis. (A) Protein
abundance of OXPHOS complexes of muscle-
specific GSK-3β KO (grey bars) and WT (white
bars) mice subjected to HLS are compared to BL
(—). (B) Gene expression of nuclear-encoded
sub-units (Ndufb3, Sdhb and Cyc1 respectively
Complex I, II and III) and the mitochondrial-en-
coded sub-unit (CoxII, respectively Complex IV)
and (C) Acadvl under BL (striated white bars)
and HLS state (striated grey bars) in muscle-
specific GSK-3β KO and WT mice are expressed
as arbitrary units (AU) in M. gastrocnemius
muscle. Representative pictures of the blots are
shown and Western blot data is corrected for
total protein loading assessed by Ponceau S
staining. Black boxes around the representative
pictures indicate that they are cut from the same
Western blot. Significant differences are tested
with an unpaired Student's t-test within genotype
comparing BL (n = 9/group) and HLS (n= 8/
group), #p≤ 0.1, *p≤ 0.05, ***p≤ 0.001.
GSK-3β: glycogen synthase kinase-3β, OXPHOS:
oxidative phosphorylation, Ndufb3:
NADH:Ubiquinone Oxidoreductase Subunit B3,
Sdhb: succinate dehydrogenase complex iron
sulfur subunit B, Cyc1: cytochrome c 1, CoxII:
Cytochrome c oxidase II, Acadvl: very long-chain
specific acyl-CoA dehydrogenase, BL: baseline,
HLS: hind limb suspension, WT: wild-type and
KO: knock-out.
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cardiac muscle [56]. We used knock-down of Pgc-1α to investigate if the
effects of pharmacological inhibition of GSK-3 on cellular energy me-
tabolism are mediated via PGC-1α. As expected, we show initial evi-
dence that increased expression of genes involved in OXPHOS (CII and
CIII sub-units) and the PGC-1 signaling network (Errα) are dependent
on GSK-3 inactivation-mediated increase in Pgc-1α. Previously, it was
reported that the gene expression of Errα [37], Sdhb and Cycs [36] are
under control of PGC-1α.
Although we did not include this in the present study, the activity of
the PGC-1α protein can be altered by post-translational modifications.
An array of kinases can modulate the activity of PGC-1, amongst others
Akt which can directly inhibit PGC-1α activity by phosphorylating
Ser570 [57]. In addition, in skeletal muscle AMP-activated protein ki-
nase (AMPK) is a well-known positive regulator of post-transcriptional
regulation of PGC-1α activity [58]. Interestingly, one study showed that
GSK-3β can phosphorylate PGC-1α thereby labeling it for intra-nuclear
proteasomal degradation, suggesting stabilization of PGC-1α resulting
in increased protein abundance upon GSK-3β inactivation [59]. This
suggests that the kinase activity of GSK-3β is an important aspect of the
molecular mechanism by which GSK-3β regulates oxidative gene ex-
pression and expression of constituents of the PGC-1 signaling network.
Another example of post-transcriptional regulation of the PGC-1α
protein is activation via SIRT-dependent deacetylation in response to
high NAD+ levels [60]. However, in our study we did not investigate
phosphorylation or acetylation status or intra-nuclear levels of PGC-1α.
In addition, future research targeting transcription factors known to
increase Pgc-1α gene expression could reveal the potential mechanism
of how GSK-3β knock-down increases transcription of Pgc-1α and its
downstream targets. In this regard, as AMPK activation is known to
increase transcription of the PGC-1α gene [61] and interplay between
AMPK and GSK-3β has been described [62,63], AMPK activation may
also play a role. Interestingly, GSK-3 can inhibit AMPK by the inhibitory
phosphorylation of Thr479 of the α-subunit of AMPK [64]. Therefore it
is not unlikely that GSK-3β inactivation-mediated activation of AMPK
plays a role in the regulation of the transcription of the PGC-1α gene as
well as regulation of the function of the PGC-1α protein in skeletal
muscle.
Our data reveals a predominant role for the GSK-3β isoform in the
regulation of skeletal muscle oxidative phenotype compared to GSK-3α.
Specific knock-down of the GSK-3α isoform resulted in less pronounced
effects on Pgc-1α gene expression while changes in e.g. mRNA expres-
sion of OXPHOS sub-units were absent. This suggest that inactivation of
GSK-3β, and not GSK-3α, is sufficient to stimulate an oxidative phe-
notype in skeletal muscle cells and shows that besides PGC-1α, ERRα
Fig. 6. GSK-3β knock-out protects against unloading-induced decline in PGC-1α signaling constituents. Muscle-specific GSK-3β KO mice and WT littermates were subjected to HLS for
14 days.M. gastrocnemius was prepared for western blotting and qPCR analysis. (A) Protein abundance of PGC-1α, NRF-1 and TFAM of GSK-3β knock-out (grey bars) and WT (white bars)
mice subjected to HLS are compared to BL (—). (B) Gene expression of Pgc-1α and gene involved in the PGC-1 signaling network under BL (striated white bars) and HLS state (striated grey
bars) in GSK-3β KO and WT mice are expressed as arbitrary units (AU) in M. gastrocnemius muscle. Representative pictures of the blots are shown and Western blot data is corrected for
total protein loading assessed by Ponceau S staining. Black boxes around the representative pictures indicate that they are cut from the same Western blot. Significant differences are
tested with an unpaired Student's t-test within genotype comparing BL (n = 9/group) and HLS (n = 8/group), #p≤ 0.1,*p ≤ 0.05, ***p≤ 0.001. GSK-3β: glycogen synthase kinase-3β,
Pparα/δ: peroxisome proliferator-activated receptor α/δ, Pgc-1α/β: PPAR gamma coactivator-1α/β, Errα: estrogen-related receptor α, Nrf-1/2α: nuclear respiratory factor-1/2α, Tfam:
mitochondrial transcription factor A, Sirt1: sirtuin 1 and Perm1: PGC-1 and ERR-induced regulator in muscle 1, BL: baseline, HLS: hind limb suspension, WT: wild-type and KO: knock-out.
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and PERM1 are most likely important to induce increases in cellular
oxidative energy metabolism. ERRs have an important function in the
regulation of skeletal muscle oxidative metabolism. For example, ERRα
is able to induce expression of genes involved in mitochondrial bio-
genesis and OXPHOS [37]. ERRγ regulates metabolic and mitochondrial
gene expression and is necessary to increase exercise capacity in ske-
letal muscle [65]. Perm1 has recently been discovered to be a potent
muscle-specific regulator downstream of PGC-1/ERR mediated sig-
naling, as it was shown that PERM1 levels are related to physical ac-
tivity levels and that knock-down of the PERM1 protein in C2C12
myotubes decreased respiratory capacity, OXPHOS, mitochondrial
biogenesis and FAO [22]. Recently, over-expression of PERM1 in
murine skeletal muscle revealed increases in mitochondrial content and
oxidative capacity in vivo [66]. These data are in line with our ob-
servations.
In vivo, we observed that GSK-3β KO animals were protected against
unloading-induced decreases in nuclear-encoded gene expression of
OXPHOS sub-units, while the mitochondrial-encoded sub-unit of
Complex IV (CoxII) was decreased after HLS in both genotypes. It is not
unlikely that protective effect of GSK-3β knock-out upon HLS is limited
to gene expression in the nucleus, as known regulators of OXPHOS gene
expression are nuclear proteins, such as PGC-1α, NRF-1/2α and ERRs
[21].
The PI3K/Akt/GSK-3β signaling axis historically has been appre-
ciated for its role in the regulation of muscle mass. For example, GSK-3β
is required for the induction of muscle atrophy in vitro [15]. Also, it was
reported that pharmacological inactivation of GSK-3β with SB216763
protected against LPS-induced loss of muscle mass [67]. However,
muscle-specific GSK-3β KO animals were previously shown not to be
protected against inactivity-induced loss of M. gastrocnemius mass [39].
GSK-3β has been shown to modulate both protein synthesis [68] and
protein degradation pathways [15]. Besides these known effects of GSK-
3β on muscle protein turnover, in the current study, we now show for
the first time, not only that inactivation of GSK-3β enhances myotube
mitochondrial metabolism but also that muscle-specific KO of GSK-3β
protects against decrement in metabolic gene expression and expression
of the PGC-1 signaling network. Taken together, this suggests that GSK-
3β represents a nodal point interconnecting regulatory pathways in-
volved in the regulation of mitochondrial energy metabolism on the one
hand and pathways controlling muscle mass on the other hand. Recent
reports in literature support the notion that these pathways are inter-
twined [69]. For example, PGC-1α controls mitochondrial biogenesis
and oxidative metabolism, but also protects against atrophy when over-
expressed [70,71]. Furthermore, besides its regulatory role in mi-
tochondrial oxidative metabolism, PGC-1 has also been implicated in
the regulation of muscle mass. Not only has it been demonstrated that
PGC-1α transcript and protein levels sharply decrease after atrophy
induced by well-established muscle atrophy models by denervation,
fasting and inactivity but it has also been shown that over-expression of
the PGC-1α protein protects against muscle atrophy after denervation,
fasting or inactivity [70,71]. Next to PGC-1α, Akt-dependent activation
of ATP citrate lyase boosts skeletal muscle oxidative metabolism, be-
sides the well-known effects of Akt on the regulation of muscle hy-
pertrophy and atrophy [43]. Previously our group reported that muscle
fibre type distribution was largely preserved in GSK-3β KO muscle
compared to WT animals, [39]. Investigations into in vivo functional
changes such as skeletal muscle oxygen consumption or the contractile
properties of the musculature were not the primary goal of this study,
therefore we did not include these measurements. This, however, is an
interesting aspect for future research.
In conclusion, we report a novel interaction between inactivation or
loss of the GSK-3β protein and cellular energy metabolism which, in
concert with available literature, highlights an intricate link between
pathways involved in the regulation of skeletal muscle energy pro-
duction and those controlling muscle mass. However, if the effects of
inactivation of GSK-3β on mitochondrial metabolism and biogenesis are
mediated solely via PGC-1 remains to be further investigated. In addi-
tion, it remains unclear if inactivation of GSK-3β can enhance OXPHEN
in skeletal muscle of patients with altered muscle mitochondrial me-
tabolism such as seen in COPD, type 2 diabetes or chronic heart failure.
Gaining more insight in the regulation of muscle oxidative metabolism
is vital to improve understanding of the molecular mechanisms gov-
erning oxidative energy metabolism during muscle maintenance and is
required for optimizing available exercise and nutritional interventions
and to develop proficient new strategies improving skeletal muscle
oxidative metabolism and related physical functioning in chronic dis-
ease management and prevention.
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